-
341
-
342por Jelena Milosevic, Susanne Fransson, Miklos Gulyas, Thale K. Olsen, Gabriel Gallo-Oller, Diana Treis, Lotta H. M. Elfman, Margareta Wilhelm, Tommy Martinsson, Ninib Baryawno, Per Kogner, John Inge JohnsenMaterias: “...p53...”
Publicado 2021
Enlace del recurso
article -
343
-
344por Lucas Delmonico, Lívia Menezes, Marco Felipe Franco Rosa, Najla Marques de Oliveira Mattar, Eliane Barbosa Esteves, Vivian Rabello Areias, Carolina Maria de Azevedo, Gilda AlvesMaterias: “...Genes p53...”
Publicado 2013
Enlace del recurso
article -
345
-
346por Qi Liu, Ningning Liu, Qilin Shangguan, Fang Zhang, Wenjia Chai, Xiaomei Tong, Xin Zhao, Zhiwei Li, Dandan Qi, Xin Ye“... with NPM1. As it is known that NPM1 interacts with the E3 ligase HDM2 and reduces HDM2-mediated p53...”
Publicado 2019
Enlace del recurso
article -
347por Wenjun Zeng, Chunyun Zhang, Hongwei Cheng, Yun-Long Wu, Jie Liu, Zekun Chen, Jian-gang Huang, Russell Erick Ericksen, Liqun Chen, Haiping Zhang, Alice Sze Tsai Wong, Xiao-kun Zhang, Weiping Han, Jin-Zhang Zeng“... activation of AKT. Here we report RARγ as a negative regulator of p53 signaling and thus extend the oncogenic...”
Publicado 2017
Enlace del recurso
article -
348por Sweta Dash, Sean Yoder, Tania Mesa, Andrew Smith, Ling Cen, Steven Eschrich, Guillermo N. Armaiz-Pena, Alvaro N. A. Monteiro“...) and ovarian surface epithelial (iOSE11) cell lines and their isogenic pairs containing a p53 mutation (iFTSEC...”
Publicado 2021
Enlace del recurso
article -
349“... neuronal necrosis. Our data indicated that p53 was likely one such protein, because p53 was accumulated...”
Enlace del recurso
article -
350por Akechai Im-aram, Lee Farrand, Seung-Min Bae, Gwonhwa Song, Yong Sang Song, Jae Yong Han, Benjamin K Tsang“... therapeutic strategies for this deadly disease. Akt and p53 are determinants of cisplatin sensitivity. Rictor...”
Publicado 2013
Enlace del recurso
article -
351“... p53 gene and to avoid conventional production method of Gold nanoparticles (AuNPs) which may...”
Enlace del recurso
article -
352por Marion Gruffaz, Hongfeng Yuan, Wen Meng, Hui Liu, Sangsu Bae, Jin-Soo Kim, Chun Lu, Yufei Huang, Shou-Jiang Gao“... cancer. XPO1 inhibition induced cell cycle arrest through p53 activation, but the mechanisms of p53...”
Publicado 2019
Enlace del recurso
article -
353“... p53 mutations have also been detected with high frequency as early events. However, the molecular...”
Enlace del recurso
article -
354por Tatsuya Sakaguchi, Jose Isagani B. Janairo, Mathieu Lussier-Price, Junya Wada, James G. Omichinski, Kazuyasu Sakaguchi“... was achieved by conjugating the silver specific TBP biomineralization peptide to the p53 tetramerization domain...”
Publicado 2017
Enlace del recurso
article -
355“... in cancer. Through an incoherent feedforward loop, chemotherapy drugs not only activate p53 to induce cell...”
Enlace del recurso
article -
356por Tokuhiro Chano, Kaichiro Ikebuchi, Yasuko Ochi, Hitosuke Tameno, Yasuhiko Tomita, Yufen Jin, Hideo Inaji, Makoto Ishitobi, Koji Teramoto, Ichiro Nishimura, Kahori Minami, Hirokazu Inoue, Takahiro Isono, Masao Saitoh, Taketoshi Shimada, Yasuo Hisa, Hidetoshi Okabe“...) of the RB1 promoter. Here, we identified hSNF5 and p53 as the binding partners of RB1CC1...”
Publicado 2010
Enlace del recurso
article -
357“...: Murine double minute 2 (MDM2) and 4 (MDM4) are known as the main negative regulators of p53, a tumor...”
Enlace del recurso
article -
358“...P73, one member of the tumor suppressor p53 family, shares highly structural and functional...”
Enlace del recurso
article -
359“... receptor (EGFR, also known as HER1), the androgen receptor, and p53, are key molecules in breast cancer...”
Enlace del recurso
article -
360por Selvakumar Anbalagan, Cecilia Ström, Jessica A. Downs, Penny A. Jeggo, David McBay, Anna Wilkins, Kai Rothkamm, Kevin J. Harrington, John R. Yarnold, Navita Somaiah“...-type (WT) p53 and intact non-homologous end-joining (NHEJ). Using single or split-doses of radiation...”
Publicado 2021
Enlace del recurso
article